AP26113
货号：
19778-25mg 基本售价：
8666.0 元 规格：
25 mg
产品信息
概述| 货号 | 19778-25mg |
| 描述 | AP26113 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK; IC50< 100 nM in Ba/F3 cells).1,2 It is a pan-ALK inhibitor that also inhibits several ALK mutants that confer resistance to other ALK inhibitors, such as crizotinib (Item No. 12087), ceritinib (Item No. 19374), and CH5424802 (Item No. 18516).1,2 AP26113 blocks ALK activity and reduces growth in neuroblastoma cells, mouse xenograft, and Drosophila model systems harboring constitutively active ALK variants.3 |
| 别名 | Brigatinib; |
性能| 供应商 | Cayman |
| 应用文献 |
1.Ceccon, M.,Mologni, L.,Bisson, W., et al. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol. Cancer Res. 11(2), 122-132 (2013).
2.Katayama, R.,Khan, T.M.,Benes, C., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proceedings of the National Academy of Sciences of the United States of America 108(18), 7535-7540 (2011).
3.Siaw, J.T.,Wan, H.,Pfeifer, K., et al. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget 7(20), 29011-29022 (2016).
|
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 584.1 |
| 分子式 | C29H39ClN7O2P |
| CAS号 | 1197953-54-0 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
